Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

November 2022 | 71 pages | ID: E07A6887BD7EEN
Global Markets Direct

Abstracts

Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Drugs In Development, 2022, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Encephalopathy - Overview
Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalopathy - Companies Involved in Therapeutics Development
ANLBio Co Ltd
Argenica Therapeutics Ltd
Biom Therapeutics LLC
BrainRepair UG
F. Hoffmann-La Roche Ltd
Gene Therapy Research Institution Co Ltd
Hope Biosciences LLC
Jazz Pharmaceuticals Plc
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Mononuclear Therapeutics Ltd
Orphan Star Therapeutics LLC
Pfizer Inc
Pharmazz Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
Rohto Pharmaceutical Co Ltd
SL Bigen Co Ltd
Worphmed Srl
Encephalopathy - Drug Profiles
Alda-1 - Drug Profile
Product Description
Mechanism Of Action
ANL-302 - Drug Profile
Product Description
Mechanism Of Action
ARG-007 - Drug Profile
Product Description
Mechanism Of Action
BIO-018 - Drug Profile
Product Description
Mechanism Of Action
BM-1021 - Drug Profile
Product Description
Mechanism Of Action
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
CL-2020 - Drug Profile
Product Description
Mechanism Of Action
diazoxide - Drug Profile
Product Description
Mechanism Of Action
Drugs to Target SLC2A1 for Glut1 Deficiency Syndrome - Drug Profile
Product Description
Mechanism Of Action
estetrol - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate SLC2A1 for GLUT1 Deficiency Syndrome - Drug Profile
Product Description
Mechanism Of Action
GT-0006X - Drug Profile
Product Description
Mechanism Of Action
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
melatonin - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody to Inhibit IL-2 for Encephalopathy, Graft Versus Host Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
remestemcel-L - Drug Profile
Product Description
Mechanism Of Action
RLS-0071 - Drug Profile
Product Description
Mechanism Of Action
sovateltide - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Anemia and Hypoxic Ischemic Encephalopathy - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
Product Description
Mechanism Of Action
THDG-3 - Drug Profile
Product Description
Mechanism Of Action
UDI-001 - Drug Profile
Product Description
Mechanism Of Action
Encephalopathy - Dormant Projects
Encephalopathy - Discontinued Products
Encephalopathy - Product Development Milestones
Featured News & Press Releases
Oct 04, 2022: Argenica receives $1.38m R&D Tax Incentive cash refund for FY22
Sep 29, 2022: Further positive preclinical results for arg-007 in hypoxic-ischaemic encephalopathy
Aug 29, 2022: Pharmazz announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates
Jun 23, 2022: USA FDA grants Fast Track Designation to ReAlta Life Sciences’ lead compound RLS-0071 for the treatment of Hypoxic-Ischemic Encephalopathy in neonates
Jun 02, 2022: ReAlta doses first subjects in Phase Ib severe asthma therapy trial
May 10, 2022: Germany’s BfArM approves ReAlta Life Science’s phase 1b inhaled LPS challenge trial to support development of RLS-0071 in severe asthma
Apr 27, 2022: ReAlta Life Sciences partners with Hope for HIE to improve neonatal brain injury outcomes and quality of life
Apr 04, 2022: ReAlta Life Sciences’ RLS-0071 demonstrates excellent safety profile and confirmed target engagement in first-in-human phase 1 clinical trial
Mar 31, 2022: ReAlta gets FDA clearance for Phase II HIE therapy trial in neonates
Mar 04, 2022: ReAlta Life Sciences announces poster presentation at the American Academy of Neurology 2022 Annual Meeting
Feb 03, 2022: Pharmazz submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates
Dec 09, 2021: Argenica to be granted patent protection in the United States, one of the world’s largest healthcare markets
Nov 16, 2021: MPO data presented at ACR 2021
Nov 03, 2021: Argenica Therapeutics: Positive preclinical data for ARG-007 neuroprotection in hypoxicischaemic encephalopathy
May 18, 2021: ReAlta Life Sciences expands phase 1 clinical trial of RLS-0071 to include three multiple-ascending dose cohorts and an additional single ascending dose cohort
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Encephalopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Encephalopathy - Pipeline by ANLBio Co Ltd, 2022
Encephalopathy - Pipeline by Argenica Therapeutics Ltd, 2022
Encephalopathy - Pipeline by Biom Therapeutics LLC, 2022
Encephalopathy - Pipeline by BrainRepair UG, 2022
Encephalopathy - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Encephalopathy - Pipeline by Gene Therapy Research Institution Co Ltd, 2022
Encephalopathy - Pipeline by Hope Biosciences LLC, 2022
Encephalopathy - Pipeline by Jazz Pharmaceuticals Plc, 2022
Encephalopathy - Pipeline by JS Genetics Inc, 2022
Encephalopathy - Pipeline by Mesoblast Ltd, 2022
Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, 2022
Encephalopathy - Pipeline by Mononuclear Therapeutics Ltd, 2022
Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, 2022
Encephalopathy - Pipeline by Pfizer Inc, 2022
Encephalopathy - Pipeline by Pharmazz Inc, 2022
Encephalopathy - Pipeline by ProThera Biologics Inc, 2022
Encephalopathy - Pipeline by ReAlta Life Sciences Inc, 2022
Encephalopathy - Pipeline by Rohto Pharmaceutical Co Ltd, 2022
Encephalopathy - Pipeline by SL Bigen Co Ltd, 2022
Encephalopathy - Pipeline by Worphmed Srl, 2022
Encephalopathy - Dormant Projects, 2022
Encephalopathy - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Encephalopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022